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Abstract Myosin is dephosphorylated by distinct forms of
protein phosphatase 1 (PP1) in smooth muscle and skeletal
muscle that are composed of PP1 complexed to different
regulatory subunits. The smooth muscle myosin phosphatase
(smPP1M) has been characterised previously and is composed of
PP1L complexed to M110 and M21 subunits that enhance the
dephosphorylation of smooth muscle myosin, but not skeletal
muscle myosin. In contrast, the regulatory subunit(s) of skeletal
muscle myosin phosphatase (skPP1M) greatly enhance(s) the
dephosphorylation of skeletal muscle myosin. Here we identify a
regulatory subunit of skPP1M as the product of the MYPT2
gene, a protein whose sequence is 61% identical to the M110
subunit of smPP1M. Surprisingly, the M21 subunit of smPP1M
appears to be produced from the same gene that encodes
MYPT2.
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1. Introduction
Protein phosphatase 1 (PP1), one of the major protein ser-
ine/threonine phosphatases of eukaryotic cells, participates in
the control of a variety of cellular functions that include gly-
cogen metabolism, muscle concentration, protein synthesis
and pre-mRNA splicing (reviewed in [1^3]). It is now estab-
lished that each of these physiological processes is regulated
by a distinct form of PP1 in which the phosphatase catalytic
subunit is complexed to speci¢c targeting subunits containing
an Arg/Lys-Val/Ile-Xaa-Phe/Trp motif that binds to a hydro-
phobic groove on the surface of PP1 [2,4,5]. These proteins
not only direct PP1 to particular subcellular locations, but
also modify its speci¢city in unique ways and confer the abil-
ity to be regulated by extracellular signals.
A form of PP1 that is associated with myo¢brils [6] and has
enhanced myosin phosphatase activity compared to the free
catalytic subunit [7] was identi¢ed in skeletal muscle many
years ago and termed PP1M. An enzyme with these properties
was highly puri¢ed from the myo¢brillar fraction of skeletal
muscle and shown to be a complex between the catalytic sub-
unit of PP1 and another protein(s) that greatly enhanced the
rate of dephosphorylation of skeletal muscle myosin [8]. Sub-
sequently, two such forms of skeletal muscle PP1M were re-
solved by chromatography on MonoQ termed PP1MK and
PP1ML. Both enzymes were heterodimers in which the PP1
catalytic subunit was complexed to proteins with apparent
molecular masses of 33 kDa (MK) and 50 kDa (ML) [9].
A form of PP1M was puri¢ed to homogeneity from chicken
gizzard smooth muscle and shown to be composed of the L-
isoform of PP1 bound to an ‘M complex’ consisting of two
other proteins with apparent molecular masses of 130 kDa
and 20 kDa [10]. Subsequent cDNA cloning revealed that
the true molecular masses of the latter proteins were 110
kDa [11] and 21 kDa [12] and they were therefore termed
the M110 and M21 subunits. cDNAs encoding proteins that
are highly homologous to the M110 subunit from avian giz-
zard were also cloned from mammalian libraries [12^14]. The
M110 subunit from chicken gizzard is not only complexed to
the M21 subunit, but also to PP1 [10] and the Arg-Val-Lys-
Phe sequence near its N-terminus appears to be critical for
interaction with the phosphatase catalytic subunit [15]. In
contrast the binding site for the M21 subunit is near the C-
terminus of the M110 subunit [15]. Both the M110 and M21
subunits are myosin-binding proteins [16].
The binding of the chicken gizzard M110 subunit to PP1 was
found to cause a several-fold enhancement of the rate of de-
phosphorylation of smooth muscle myosin, but did not in-
crease the rate of dephosphorylation of skeletal muscle myo-
sin [10]. In contrast, the equivalent proteins in skeletal muscle
enormously enhanced (25-fold) the rate at which PP1 dephos-
phorylated skeletal muscle myosin, with a more modest (4-
fold) e¡ect on the dephosphorylation of smooth muscle my-
osin [9,10]. These observations indicated that MK and ML
from skeletal muscle were distinct gene products from their
counterparts in smooth muscle.
Recently, a cDNA was cloned from a human brain library
encoding MYPT2 (myosin phosphatase targeting subunit 2), a
110 kDa protein whose sequence is 61% identical to that of
the M110 subunit from smooth muscle [17]. However, the
mRNA encoding MYPT2 was most abundant in cardiac
muscle and skeletal muscle [17]. Here we show by peptide
sequencing that the 33 kDa MK and 50 kDa ML subunits
of skeletal muscle PP1MK and PP1ML correspond to N-ter-
minal fragments of MYPT2, indicating that MYPT2 encodes
the myosin-targeting subunit of skeletal muscle PP1M.
The C-terminal 72 residues of the M110 subunit from chick-
en gizzard are 43% identical to residues 87^161 of the M21
subunit [12]. However, a second form of the M110 subunit
from avian or mammalian smooth muscle can be produced
by alternative splicing, whose C-terminal sequence is ex-
tremely similar (but not identical) to the C-terminal 50 resi-
dues of the M21 subunit from chicken gizzard [12]. These
observations led us to speculate that the M21 subunit from
chicken gizzard might be transcribed from a second M110 gene
[12]. This hypothesis appears to be correct because the amino
acid sequence of the M21 subunit from chicken gizzard is
virtually identical to the C-terminus of the protein encoded
by the human MYPT2 gene.
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2. Materials and methods
2.1. Isolation of tryptic peptides from rabbit skeletal muscle PP1M
PP1MK and PP1ML were puri¢ed to homogeneity from the myo¢-
brillar fraction of rabbit skeletal muscle by a⁄nity chromatography
on microcystin-Sepharose and chromatography on MonoQ [9]. The
preparations were subjected to SDS-polyacrylamide gel electrophore-
sis and the bands corresponding to PP1, MK and ML, excised and
digested with trypsin [18]. The resulting peptides were chromato-
graphed on a C18 column and analysed on an Applied Biosystems
476A Amino Acid Sequencer [18].
2.2. Preparation of tissue extracts
Tissues were rapidly removed post mortem, frozen in liquid nitro-
gen, ground in a pestle and mortar and homogenised with 6 vols of 20
mM Tris-HCl pH 7.5, 500 mM NaCl, 1 mM EDTA, 1 mM EGTA,
0.1% (by vol) 2-mercaptoethanol, 0.2 mM phenylmethylsulphonyl £u-
oride, 1 mM benzamidine and 10 Wg/ml of the proteinase inhibitors
leupeptin, chymostatin, pepstatin and lima bean trypsin inhibitor. The
homogenates were then centrifuged at 13 000Ug for 5 min at 4‡C, the
supernatants removed and denatured in SDS by heating for 5 min at
95‡C.
2.3. Antibodies and immunoblotting
Polyclonal antibodies were raised in sheep against the PP1M hol-
oenzyme from chicken gizzard. A⁄nity-puri¢ed antibodies that rec-
ognise the M110 subunit (but not the M21 subunit) were obtained by
passing the antiserum through Sepharose to which the C-terminal 290
residues of the chicken gizzard M110 subunit had been coupled [15].
Antibodies that recognise the M21 (but not the M110 subunit) of
chicken gizzard PP1M were obtained in an identical manner, except
that the antiserum was passed through a Sepharose column to which
the chicken gizzard M21 subunit had been coupled covalently [15]. The
speci¢city of both antibodies has been demonstrated previously [15].
3. Results and discussion
Previous peptide sequencing studies indicated that the ma-
jor isoform of the PP1 catalytic subunit associated with the
‘M subunit’ from skeletal muscle was the L-isoform [8] (also
termed PP1N [19]) and this ¢nding was con¢rmed in the
present work by sequencing additional peptides. Sequence
analysis of the catalytic subunit of PP1 that is complexed to
MK and ML revealed six tryptic peptides whose sequences
were common to all three human isoforms of PP1, PP1K,
PP1L and PP1Q, and two that were speci¢c to PP1L (Fig. 1).
Since each peptide was recovered from the tryptic digest in
similar amounts, these results indicate that PP1L is the major
PP1 isoform that is complexed to MK and ML in skeletal
muscle; i.e. the same isoform that is complexed to the glyco-
gen-targeting (GM) subunit of PP1 in skeletal muscle [20] and
to the M110 subunit in chicken gizzard [10]).
A number of tryptic peptides were also isolated after tryptic
digestion of MK and ML from rabbit skeletal muscle and their
sequences are shown in Fig. 1. All were virtually identical to
particular regions of the protein encoded by the human
MYPT2 gene [17] with 94 identities out of 100 residues se-
quenced. The peptide sequences were much less similar to
MYPT1 (65% identity), the human homologue of the smooth
muscle M110 subunit [12,14]. Since the predicted molecular
mass of MYPT2 is 110 kDa, these results indicate that MK
and ML are both derived from MYPT2 by limited proteolysis
during extraction and/or puri¢cation from skeletal muscle. All
the peptides sequenced are located within the residues 81^412
of MYPT2, indicating that MK and ML are N-terminal frag-
ments of this protein. Since the complexes formed between
MK and PP1 or ML and PP1 both have greatly enhanced
activity towards skeletal muscle myosin compared to the
free PP1 catalytic subunit, the information required to interact
with PP1 and enhance its myosin phosphatase activity are
both contained in the N-terminal portion of MYPT2. This
¢nding is as anticipated, since the ¢rst 309 residues of M110
subunit from smooth muscle interact with PP1 and enhance
the dephosphorylation of smooth muscle myosin in a similar
manner to the full length protein [15]. The ¢rst 300 residues of
the skeletal muscle and smooth muscle proteins both contain
seven ankyrin repeats, the ¢rst of which is preceded by a
canonical PP1-binding motif (see Section 1). In MYPT2,
this Arg-Val-Arg-Phe sequence is located between residues
53 and 56 [17]. It will clearly be of great interest to understand
why the N-terminal domain of the M110 subunit from smooth
muscle stimulates the dephosphorylation of smooth muscle
myosin, but not skeletal muscle myosin, and why MYPT2
enhances the dephosphorylation of skeletal muscle myosin
far more than it enhances the dephosphorylation of smooth
muscle myosin.
The C-terminus of the M110 subunit from smooth muscle is
homologous, but not identical, to the M21 subunit from
smooth muscle (Fig. 2). Remarkably, however, the last 120
residues of chicken gizzard M21 (residues 67^186) show 91%
identity and nearly 100% similarity (if highly conservative
replacements are included) to the last 120 residues of human
MYPT2 (Fig. 2). This suggests that the M21 subunit from
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Fig. 1. Amino acid sequences of tryptic peptides from PP1MK and
PP1ML. The catalytic and regulatory subunits of rabbit skeletal
muscle PP1MK and PP1ML were resolved by SDS-polyacrylamide
gel electrophoresis, digested with trypsin and the peptides separated
and sequenced as in Section 2. The positions of these peptides in
the sequence of the human MYPT2 are indicated. Underlined resi-
dues are unique to the L-isoform of PP1. An X indicates residues
that could not be identi¢ed unambiguously.
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chicken gizzard is likely to be produced from the gene encod-
ing an avian homologue of MYPT2. Similarity with MYPT2
disappears N-terminal to residue 30 of the M21 subunit (Fig.
2), suggesting that the N-terminal 30 residues may be encoded
within an intron of the MYPT2 gene. If the M21 subunit is
indeed produced from the MYPT2 gene, then anti-M21 anti-
bodies should recognise a 21 kDa protein in smooth muscle
and a 110 kDa protein in tissues where the full length MYPT2
protein is expressed. The results presented in Fig. 3 are con-
sistent with this scenario. The antibody raised against M21
from chicken gizzard recognised a 22 kDa protein in ¢ve rat
smooth muscles (small intestine, aorta, stomach, bladder and
uterus) whose electrophoretic mobility was slightly slower
than that of the M21 subunit from chicken gizzard, but the
same antibody detected a 110 kDa protein in rat brain and rat
cardiac muscle (Fig. 3). Similar results were obtained in chick-
en tissues, where the M21 antibody recognised 20 kDa and/or
21 kDa proteins in three smooth muscles (gizzard, aorta and
small intestine), but recognised 110 kDa proteins in brain and
cardiac muscle that were also expressed (albeit more weakly)
in small intestine and aorta (data not shown). Brain and car-
diac muscle are the two human tissues where the MYPT2
protein was shown to be expressed most prominently [17].
The myosin P-light chain present in cardiac muscle is not
the same gene product as the P-light chain found in skeletal
muscle [21]. The expression pattern of MYPT2 therefore sug-
gests that this protein may not only enhance the dephospho-
rylation of skeletal muscle myosin, but also the dephospho-
rylation of cardiac myosin and brain myosin.
Although the mRNA encoding MYPT2 is highly expressed
in skeletal muscle, Fujioka et al. [17] failed to detect any
MYPT2 protein in this tissue by immunoblotting. Our anti-
body raised against the chicken gizzard M21 subunit also
failed to detect an immunoreactive 110 kDa protein in skeletal
muscle extracts, although it weakly recognised a 90 kDa pro-
tein that might correspond to a proteolytic fragment of
MYPT2 (Fig. 3). However, MYPT2 is clearly expressed in
skeletal muscle because we isolated it as fragments of a sub-
unit of the major myosin phosphatase in this tissue, and a 55
kDa fragment of MYPT2 was also detected recently by others
[22] as a myo¢brillar protein from skeletal muscle that binds
to microcystin-Sepharose. The failure to detect MYPT2 by
immunoblotting could be explained by its low abundance,
since the isolation of PP1M requires over 100 000-fold puri¢-
cation from the myo¢brillar fraction of skeletal muscle [8,9],
in contrast to the much smaller (1000-fold) puri¢cation
needed to isolated PP1M from the myo¢brils of avian smooth
muscle [10]. This low level is consistent with the slow rate of
dephosphorylation of the skeletal muscle myosin P-light chain
in vivo [23]. Alternatively, the extreme susceptibility of the C-
terminus of MYPT2 to proteolysis in skeletal muscle extracts
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Fig. 3. Immunoblotting of rat tissues with antibody raised against
the M21 subunit from chicken gizzard. Tissue extracts (15 Wg extract
protein, except for chicken gizzard where 10 Wg protein was used)
were electrophoresed on 15% SDS-polyacrylamide gels, transferred
to nitrocellulose and immunoblotted with a⁄nity-puri¢ed anti-M21
antibody using the enhanced chemiluminescence detection system
(Amersham). Lane 1, PP1M (0.1 Wg) puri¢ed from chicken gizzard
[10] ; lane 2, small intestine; lane 3, aorta; lane 4, brain; lane 5, car-
diac muscle; lane 6, stomach; lane 7, bladder; lane 8, uterus; lane
9, skeletal muscle; lane 10, chicken gizzard. The positions of the
marker proteins glycogen phosphorylase (97 kDa), bovine serum al-
bumin (66 kDa), ovalbumin (43 kDa), carbonic anhydrase (29 kDa)
and soybean trypsin inhibitor (20 kDa) are indicated.
Fig. 2. Alignment of the M21 subunit from turkey gizzard with the C-termini of human MYPT2, human MYPT1 and the rat aorta M110 sub-
unit. Identities with the M21 subunit are highlighted in black and the most conservative replacements are shaded grey. The sequences are taken
from [11,12,14,17].
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may have prevented detection by our antibody which recog-
nises the C-terminus of the protein.
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